NCT04851015View on ClinicalTrials.gov

Low Dose Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis Jirovecii Pneumonia

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

January 31, 2025

Primary Completion Date

March 31, 2028

Study Completion Date

June 30, 2028

Conditions
PneumocystisPneumocystis PneumoniaPneumocystis Jirovecii InfectionPneumocystis InfectionsPneumocystis Carinii InfectionPneumocystosis; Pneumonia (Etiology)Pneumocystis Carinii; Infection, Resulting From HIV DiseasePneumocystosis Associated With AIDS
Interventions
DRUG

trimethoprim-sulfamethoxazole

10mg/kg/day of TMP component

DRUG

trimethoprim-sulfamethoxazole

15mg/kg/day of TMP component

Trial Locations (1)

H4A3J1

McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital), Montreal

All Listed Sponsors
lead

McGill University Health Centre/Research Institute of the McGill University Health Centre

OTHER